肌层浸润性膀胱癌的放化疗与根治性膀胱切除术比较:基于美国国家癌症数据库的倾向评分加权对比分析
该研究利用美国国家癌症数据库分析2004—2014年肌层浸润性膀胱癌患者,比较根治性膀胱切除术(RC)与放化疗(CMT)的总生存(OS)。纳入RC组15854例、CMT组2083例,RC组5年OS为40.4%,CMT组为29.4%,多因素分析及倾向评分加权分析均显示CMT组OS较短。
要点
- RC组5年OS为40.4%,CMT组为29.4%(P<.001)。
- 倾向评分加权分析显示CMT组OS较短(HR 1.18,95%CI 1.07-1.30;P<.001)。
- 亚组分析显示N0/N1期患者RC组有生存获益(HR 1.21,95%CI 1.09-1.33;P<.001)。
核心结论
- 肌层浸润性膀胱癌患者治疗后1年OS在RC组高于CMT组。
- 需进一步研究以确定特定患者的最佳治疗方案。
研究设计与样本
- 利用美国国家癌症数据库的倾向评分加权对比分析。
- 纳入2004—2014年诊断的肌层浸润性膀胱癌患者,RC组15854例、CMT组2083例。
- 采用加权Kaplan-Meier法估计生存,倾向评分加权Cox比例风险模型评估临床病理特征与结局的关联。
主要发现
- RC组5年OS为40.4%,CMT组为29.4%(P<.001)。
- 多因素分析显示CMT组OS较短(HR 1.15,95%CI 1.08-1.22;P<.001)。
- 倾向评分加权分析显示CMT组OS较短(HR 1.18,95%CI 1.07-1.30;P<.001)。
- 交互项分析显示年龄小于70岁的患者RC后生存更好(HR 1.61,95%CI 1.34-1.93;P<.001)。
- 亚组分析显示N0/N1期患者RC组有生存获益(HR 1.21,95%CI 1.09-1.33;P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究以确定特定患者的最佳治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To address the overarching question whether chemoradiation therapy (CMT) offers overall survival (OS) similar to that of radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC), we performed analyses using the National Cancer Database. MATERIALS AND METHODS: Patients diagnosed with MIBC in 2004-2014 who underwent RC or received primary CMT were identified in the National Cancer Database. Survival was estimated using the weighted Kaplan-Meier method, and propensity score-weighted Cox proportional hazards model were used to evaluate association of clinicopathologic features with outcome. RESULTS: Of 484,367 patients with a diagnosis of bladder cancer, 35,856 underwent RC and 4050 received CMT. After applying the exclusion/inclusion criteria, data for 15,854 patients who underwent RC and 2083 who received CMT were available for analysis. Five-year OS was 40.4% in the RC group and 29.4% in the CMT group (P <.001). OS was significantly shorter in the CMT group than in the RC group in both multivariate analysis (hazards ratio [HR] 1.15, 95% CI 1.08-1.22; P <.001) and propensity score-weighted analysis (HR 1.18, 95% CI 1.07-1.30; P <.001). Interaction terms indicated better survival after RC in patients younger than 70 years (HR 1.61, 95% CI 1.34-1.93; P <.001); subgroup analyses identified a survival benefit in patients with N0/N1 disease who underwent RC (HR 1.21, 95% CI 1.09-1.33; P <.001). CONCLUSION AND RELEVANCE: OS after 1 year of treatment was increased in RC group compared to CMT group in patient with MIBC. Further studies are required to identify optimal treatment for specific patients.
引用
- Kaushik D, Wang H, Michalek J, et al. Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database. Urology. 2019. PMID: 31401220. doi:10.1016/j.urology.2019.05.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。